Explore by goal
Explore clinician-guided pain and inflammation pathways, including low-dose naltrexone and select recovery programs when appropriate.
What to consider
Explore clinician-guided pain and inflammation pathways, including low-dose naltrexone and select recovery programs when appropriate.
4 programs
Make your recovery goals part of a clear conversation. BPC-157 is a peptide studied for tendon and tissue repair. A clinician reviews your goals, the formula and individual suitability.
Medication, shipping, clinician review and ongoing support included.
Explore program
Bring your skin and recovery goals into one conversation. KLOW combines BPC-157, GHK-Cu, KPV and TB-500, peptides explored for skin structure, inflammation and tissue repair. A clinician reviews your goals, the formula and individual suitability.
Medication, shipping, clinician review and ongoing support included.
Explore program
Recovery deserves more than guesswork. TB-500 is a peptide explored for tissue repair and wound healing. A clinician reviews your goals, the formula and individual suitability.
Medication, shipping, clinician review and ongoing support included.
Explore program
Because getting back to what you love matters. Wolverine pairs BPC-157 and TB-500, two peptides studied for tissue repair and recovery. Explore a two-peptide injection with clinician guidance, clear expectations and ongoing support.
Medication, shipping, clinician review and ongoing support included.
Explore programConsider This
FAQ
No. Naltrexone is FDA approved for opioid- and alcohol-related indications at standard doses; low-dose use for chronic pain or inflammation-related conditions is off label.
Naltrexone blocks opioid receptors and can create serious problems for people using opioid medications or with opioid dependence. A clinician must review all prescriptions, nonprescription products and recent opioid exposure.
The evidence is evolving and varies by condition. A recent randomized-trial meta-analysis found mixed results overall, with a signal in fibromyalgia but increased adverse events versus placebo. It should not be marketed as a proven universal pain treatment.
No. New weakness, loss of bowel or bladder control, chest pain, severe injury, fever with pain or other red flags need urgent or in-person assessment.
Authoritative starting points
Private clinician review
Program pages are educational. Eligibility, treatment, route and availability are determined only after an independent clinical evaluation.
